Business
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis Preliminary case reports suggesting clinical benefit underscore unmet need for development of a standardized, FDA-approved statin therapy evaluated in rigorous, well-designed clinical trials WAYNE, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing
About this update from Palvella Therapeutics, Inc.
[{"type":"image","alt":"Palvella Therapeutics Inc.","displaySize":"","headline":null,"caption":"Palvella Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/4b273ae029a5e8cb06a3771e7b41e04d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IZ4VZ0Qdm50kE5TTbiIBBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4b273ae029a5e8cb06a3771e7b41e04d","width":300,"height":300}},"lazy":false},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:100%;width:100%;min-width:100%;text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":"Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis","length":125,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":"Preliminary case reports suggesting clinical benefit underscore unmet need for development of a standardized, FDA-approved statin therapy evaluated in rigorous, well-designed clinical trials","length":190,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]}],"length":321},{"type":"text","content":"WAYNE, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the publication of a systematic review in Clinical and Experimental Dermatology which synthesizes available published clinical evidence on off-label statin use for cutaneous application in porokeratosis. The syst...